Results 151 to 160 of about 41,075 (183)

Neutralization and ADCC reveal divergent spike-subdomain targeting across SARS-CoV-2 vaccine platforms in an African cohort. [PDF]

iScience
Oluka GK, Katende JS, Kato L, Ankunda V, Sembera J, Ejou P, Odoch G, Namuyanja A, Kaleebu P, Serwanga J.   +9 more
europepmc   +1 more source

SARS-CoV-2 and Influenza Co-Circulation and Co-Vaccination: A Narrative Review. [PDF]

Vaccines (Basel)
Kamransarkandi M, Varyushina EA, Gorshkov AN, Stukova MA.   +3 more
europepmc   +1 more source

Antibody and B-Cell Responses to PHH-1V81 XBB.1.16-Adapted SARS-CoV-2 Booster Vaccination Are Associated With Variant Neutralization. [PDF]

J Med Virol
Torres C, Jiménez A, Deulofeu M, Prenafeta A, Dobaño C, Moncunill G, Ferrer L, Molinos-Albert LM.   +7 more
europepmc   +1 more source

Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents. [PDF]

Pediatr Infect Dis J
Gwak E, Choe SA, Kim K, Bolormaa E, Gschwend MH, Fix J, Vadivale M, Rousculp MD, Choe YJ.   +8 more
europepmc   +1 more source

First Paediatric Case of mRNA COVID-19 Vaccine Associated New Onset Systemic Myasthenic Crisis. [PDF]

Sisli Etfal Hastan Tip Bul
Kirik S, Agar M, Akyol HG, Kirik Y.
europepmc   +1 more source

Autoantibody production in pregnancy: relationship with mRNA BNT162b2 immunization, active COVID-19, and pre-eclampsia. [PDF]

Front Immunol
da Silva MC, Diniz GTN, Correia MJDS, da Silva NCH, Barbosa CRM, Ferreira ALCG, de Melo MIB, de Magalhães JJF, Donadi EA, Souza AI, Lucena-Silva N.   +10 more
europepmc   +1 more source

A Reanalysis of the FDA's Benefit-Risk Assessment of Moderna's mRNA-1273 COVID Vaccine Based on a Model Incorporating Benefits Derived from Prior COVID Infection. [PDF]

Vaccines (Basel)
Bourdon PS, Duriseti R, Gromoll HC, Dalton DK, Bardosh K, Krug AE.   +5 more
europepmc   +1 more source

A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial. [PDF]

Trials
Musa AZ, Salako AO, Ayorinde JB, Ekama S, Odubela OO, Ige F, Idigbe IE, Ajibaye O, Odubela OR, Egharevba H, Ekpenyong M, Adeneye K, Folahanmi AT, Olojo II, Fowora MA, Okwuraiwe A, Elemuwa U, Ezenyi I, Fraden B, Oba A, Idris GA, Jimoh Y, Akande IR, Ogunwale J, Nwaiwu SO, Omale OL, Oyewunmi OO, Ezeanowi R, Agbabiaka A, Eyinade O, Osho A, Garba A, Yahya B, Musa BM, Ezejiofor O, Ejiro B, Iwalokun BA, Adigwe OP, Adeyeye MC, Faisal S, Ezechi OC, Salako BL.   +41 more
europepmc   +1 more source

Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination. [PDF]

Sci Transl Med
Cao X, Manhas A, Chen YI, Caudal A, Mondejar-Parreño G, Zhu W, Liu W, Kong X, Zeng W, Liu L, Zhao SR, Jahng JWS, Utz PJ, Nadeau KC, Nishiga M, Wu JC.   +15 more
europepmc   +1 more source

Neutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses. [PDF]

Front Immunol
Caetano BLL, Pinto PBA, Pacheco AR, Lage AR, Pereira ASG, Nascimento AVP, Machado TR, Paulino A, Medeiros TL, Fernandes-Siqueira LO, Da Poian AT, Horbach IS, Azevedo AS, Costa SM, Alves AMB.   +14 more
europepmc   +1 more source